Showing results (731-740 of 2,229) with videos related to

Sort By:
Pageof 223
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Radiotoxicity of iodine-125 and other auger-electron-emitting radionuclides: background to therapyS James Adelstein, Amin I Kassis, Lisa Bodei, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Biotinylation, pharmacokinetics, and extracorporeal adsorption of humanized MAb 111In-MN14 using an avidin-affinity column in ratsZhongmin Wang, Michael Garkavij, Tomas Ohlsson, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Automated kinetic analysis of FDG uptake in living rat brain slices from dynamic positron autoradiographyGeorge Zubal, Yasuhisa Fujibayashi, Nobuyuki Maruoka, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Radiation dose to abdominal organs of the mouse due to 90Y in the urinary bladderJoel Lazewatsky, Yihong Ding, David Onthank, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Characterization of an alpha-particle irradiator for individual cell dosimetry measurementsSteven J Wang, Jenny L Whitlock, Christina Soyland, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 5, 2003
Multicellular dosimetry in voxel geometry for targeted radionuclide therapyA Malaroda, G D Flux, F M Buffa, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Effects of 13-cis-retinoic acid on chemoimmunotherapy of metastatic renal cell carcinoma--results of a retrospective analysisJan Roigas, Serdar Deger, Kasra Taymoorian, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Radiation dosimetry results from a Phase II trial of ibritumomab tiuxetan (Zevalin) radioimmunotherapy for patients with non-Hodgkin's lymphoma and mild thrombocytopeniaGregory A Wiseman, Bryan R Leigh, William D Erwin, et al.
Cancer Biotherapy & Radiopharmaceuticals|June 14, 2003
Additional radiation absorbed dose estimates for Zevalin radioimmunotherapyGregory A Wiseman, Bryan R Leigh, William L Dunn, et al.
Cancer Biotherapy & Radiopharmaceuticals|September 25, 2003
Assessment of hepatic toxicity from treatment with 90Y-SMT 487 (OctreoTher(TM)) in patients with diffuse somatostatin receptor positive liver metastasesDavid Bushnell, Yusuf Menda, Mark Madsen, et al.
Pageof 223